The effect of acotiamide on gastroesophageal reflux events and reflux symptoms in patients with refractory gastroesophageal reflux disease (GERD) who are taking acid suppressive drugs

The effect of acotiamide on gastroesophageal reflux events and reflux symptoms in patients with refractory gastroesophageal reflux disease (GERD) who are taking acid suppressive drugs - The effect of acotiamide for refractory GERD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026364

Enrollment

100

Registered

2017-03-03

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease

Interventions

acotiamide 300mg 2 weeks Placebo 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Gastric acid inhibitor refractory GERD

Exclusion criteria

Exclusion criteria: Patients with severe complications

Design outcomes

Primary

Measure	Time frame
Subject's global assessment of overall treatment efficacy at 2 weeks	—

Secondary

Measure	Time frame
Patients rated of each symptoms at 2 weeks Change of reflux pattern at 2 weeks	—

Countries

Japan

Contacts

Public ContactHiroshi Yamasita

Saiseikai Nakatsu Hospital Gastroenterology

onakaryoko0310@gmail.com0663520333

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026